Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

ClinicalTrials.gov ID: NCT04753606

Public ClinicalTrials.gov record NCT04753606. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.

Study identification

NCT ID: NCT04753606
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: NewAmsterdam Pharma; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

Obicetrapib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 18, 2021 (Actual)
Primary completion: May 24, 2021 (Actual)
Completion: Aug 30, 2021 (Actual)
Last update posted: Jul 12, 2024

2021

United States locations

U.S. sites: 19
U.S. states: 13
U.S. cities: 18

Facility	City	State	ZIP	Site status
Pinnacle Research Group	Anniston	Alabama	36207	—
National Research Institute - Huntington Park	Huntington Park	California	90255	—
National Research Institute - Wilshire	Los Angeles	California	90057	—
Clinical Trials Research	Sacramento	California	95821	—
Jacksonville Center for Clinical Research	Jacksonville	Florida	32216	—
Ocala Cardiovascular Research	Ocala	Florida	34474	—
Progressive Medical Research	Port Orange	Florida	32127	—
IACT Health	Columbus	Georgia	31904	—
Evanston Premier Healthcare Research LLC	Evanston	Illinois	60201	—
Midwest Institute for Clinical Research	Indianapolis	Indiana	46260	—
Oakland Medical Research Center	Troy	Michigan	48085	—
Diabetes and Endocrinology Consultants, P.C.	Morehead City	North Carolina	28557	—
Lillestol Research, LLC	Fargo	North Dakota	58104	—
Metabolic and Atherosclerosis Research Center	Cincinnati	Ohio	45227	—
Summit Research Group, LLC	Munroe Falls	Ohio	44262	—
Monument Health Clinical Research	Rapid City	South Dakota	57701	—
Health Concepts	Rapid City	South Dakota	57702	—
Juno Research, LL	Houston	Texas	77040	—
Manassas Clinical Research Center	Manassas	Virginia	20110	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04753606, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 12, 2024 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04753606 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →